Our research has demonstrated selective S sensitivity loss very early in diabetes and prior to irreversible complications in the eye (pre- retinopathy). The loss is selective for signals in the S cone pathways and, at least in early stages involves neither other color pathways nor the achromatic processing of signals. The deficit is revealed under bright yellow field adaptation conditions and our experiments suggest the involvement of some anomaly of the sensitivity control mechanisms beyond the receptor. (Proposed tests will identify extent of loss under conditions of neutral adaptation using spatio-chromatic modulations on computer generated video displays). The S sensitivity loss is not only associated with the more advanced retinopathic sign of edema but, we have shown on a limited study population that it closely follows the blood glucose levels of diabetics over minutes, hours or months. Our finding of direct metabolic effects on S sensitivity, as opposed to a loss associated with vascular complication of the breakdown of the blood-retina barrier, is central to a series of proposed experiments on diabetics with early and different levels of diabetic eye complications and diabetic control. The hypothesis of the existence of a critical period of reversibility of function, prior to retinopathy development is specifically explored. Related experiments will utilize both objective and psychophysical approaches to isolate the site of early diabetic complications at the molecular level in the function of RPE, the S cone receptor level with new ERG approaches to recording S cone responses, the post-receptoral inner nuclear retinal level with B-wave responses to S pathway stimulation, and chromatic pathway selectivity recorded at the striate cortex level with VEP measures. All measures are applications of instrumentation and techniques developed within the last grant period. The overall goal is to identify the earliest functional vision changes associated with the complications of diabetes that can provide insight as to the site of action of the diabetes, the prognostic indicators of impending irreversible damage to the visual system and potent indicators of the appropriate choice of treatment, and a measure of treatment efficacy for diabetic complications.
Ozawa, Glen Y; Bearse Jr, Marcus A; Adams, Anthony J (2015) Male-female differences in diabetic retinopathy? Curr Eye Res 40:234-46 |
Wolff, B E; Bearse Jr, M A; Schneck, M E et al. (2015) Color vision and neuroretinal function in diabetes. Doc Ophthalmol 130:131-9 |
Dhamdhere, Kavita P; Schneck, Marilyn E; Bearse Jr, Marcus A et al. (2014) Assessment of macular function using the SKILL Card in adults with type 2 diabetes mellitus. Invest Ophthalmol Vis Sci 55:3368-74 |
Ozawa, Glen Y; Bearse Jr, Marcus A; Harrison, Wendy W et al. (2014) Differences in neuroretinal function between adult males and females. Optom Vis Sci 91:602-7 |
Bronson-Castain, Kevin W; Bearse Jr, Marcus A; Neuville, Jessica et al. (2012) Early neural and vascular changes in the adolescent type 1 and type 2 diabetic retina. Retina 32:92-102 |
Adams, Anthony J; Bearse Jr, Marcus A (2012) Retinal neuropathy precedes vasculopathy in diabetes: a function-based opportunity for early treatment intervention? Clin Exp Optom 95:256-65 |
Tam, Johnny; Dhamdhere, Kavita P; Tiruveedhula, Pavan et al. (2012) Subclinical capillary changes in non-proliferative diabetic retinopathy. Optom Vis Sci 89:E692-703 |
Ozawa, Glen Y; Bearse Jr, Marcus A; Bronson-Castain, Kevin W et al. (2012) Neurodegenerative differences in the retinas of male and female patients with type 2 diabetes. Invest Ophthalmol Vis Sci 53:3040-6 |
Harrison, Wendy W; Chang, Ann; Cardenas, Maria G et al. (2012) Blood pressure, vessel caliber, and retinal thickness in diabetes. Optom Vis Sci 89:1715-20 |
Laron, Michal; Bearse Jr, Marcus A; Bronson-Castain, Kevin et al. (2012) Association between local neuroretinal function and control of adolescent type 1 diabetes. Invest Ophthalmol Vis Sci 53:7071-6 |
Showing the most recent 10 out of 59 publications